AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 6-KAUG 122 min read$KMDA

KAMADA LTD (KMDA): Financial results for H1 2026

KAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year

Original reporting
SEC EDGAR 6-K
Published Aug 12, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KMDA
Bullish
high confidence
Mentioned
$KMDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$KMDABullishMed
01

Why it matters

The earnings beat and reaffirmed guidance are likely to boost investor confidence and may trigger short‑term buying pressure.

02

Market read

First‑report earnings with strong growth metrics and a new $50M contract provide fresh, material information for traders.

03

What to watch

Potential regulatory or supply‑chain risks in plasma collection could temper the projected growth.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Kamada Ltd., a NASDAQ‑listed biopharma focused on plasma‑derived therapies, released its H1 2026 earnings via a Form 6‑K filing.

Company-level read

Ticker impact

$KMDABullishHigh confidence
Context

Kamada Ltd. filed a Form 6‑K reporting record‑high H1 2026 revenues of $100.2M and reaffirmed its 2026 guidance.

Expected impact

Potential upside as investors price in higher‑than‑expected earnings and solid cash flow.

Evidence & confidence

First‑time disclosure of earnings with double‑digit growth and a sizable $50M plasma sales contract provides clear, material information.

Market effects

Sector

Highlights strength in the specialty plasma‑derived therapeutics sector, supporting peers with similar product lines.

Regional

Positive for Israeli biotech and U.S. plasma‑product markets.

Global

Reinforces demand for rare‑disease therapies worldwide.

Counterpoint

What could challenge this read

If the $50M sales agreement is delayed, growth may slow, making the stock vulnerable to a pull‑back.

Key entities

  • company
    Kamada Ltd.

    Biopharmaceutical company specializing in plasma‑derived products.

  • executive
    Amir London

    Chief Executive Officer of Kamada Ltd.

Read at source← All news

Related articles

AUG 19
$KMDAMed

Kamada (KMDA) Q2 2026 Earnings Call Transcript

Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.

yahoo.com2 min
AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min